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Abstract
Background: High prices of direct acting antivirals (DAAs) for hepatitis C virus (HCV) can lead to restrictions on access
to treatment in high- and middle-income countries. An increasing number of people in these countries are treating their
HCV infection with generic drugs produced in India, China, Bangladesh or Egypt. This analysis assessed the efficacy of
generic imported DAAs.
Methods: Patients sourced generic versions of sofosbuvir (SOF), ledipasvir (LDV) and daclatasvir (DCV) from suppliers
in India, Bangladesh, China and Egypt via three buyers’ clubs. The choice of DAAs and the length of treatment were
determined on baseline RNA levels, HCV genotype and stage of fibrosis. Patient HCV RNA levels were evaluated
pre-treatment, during treatment, at end of treatment (EOT) and then for sustained virological response (SVR) at 4, 12,
and 24 weeks, normally by a treating clinician.
Results: Overall 616 patients submitted results: 199 from an Australian buyers’ club, 205 from a South-east Asian buyers’
clubs, and 212 from an Eastern European buyers’ club. Of the 616 patients treated, 276 received SOF/LDV (35 with
ribavirin [RBV]) and 340 received SOF/DCV (61 with RBV). At baseline, 61% were male, 52% had HCV genotype 1 and
11% had liver cirrhosis. The mean age was 44.3 years and the mean baseline HCV RNA was 6.9 log10 IU/mL. A rapid
virological response (RVR) was observed in 314/375 (84%) of the patients treated. Based on currently available data,
the percentage of patients with HCV RNA below the lower limit of quantification (LLoQ) was 99% (234/237) at EOT,
99% (299/303) at SVR4 and 99% (247/250) at SVR12.
Conclusions: In this analysis, treatment with imported generic DAAs achieved high rates of HCV RNA undetectability
at the end of treatment, and SVR12 in 99% of patients evaluated to date. Mass treatment with generic DAAs is a feasible
and economical alternative route of accessing curative DAAs, where the high prices for branded alternatives prevent access
to treatment.
Keywords: hepatitis C, direct acting antivirals, sofosbuvir, ledipasvir, daclatasvir
Introduction
The World Health Organization (WHO) estimates there are 71
million people chronically infected with hepatitis C virus (HCV)
worldwide, with this number rising despite the existence of an
effective cure. Up to 20% of those chronically infected will develop
cirrhosis and 2–4% hepatocellular carcinoma (HCC), causing more
than 400,000 deaths per year [1]. The recent WHO sector strategy
for viral hepatitis aims to reduce this death toll by 65% by 2030,
a scenario only feasible through increased and targeted treatment
efforts [2].
Combinations of direct acting antivirals (DAAs), new oral, well-
tolerated medications, can achieve over 90% sustained virological
response (SVR) rates, which is considered a cure of HCV infection
[3]. The importance of two of these combinations led to their
inclusion in the 2016 WHO Essential Medicines List: sofosbuvir/
ledipasvir (SOF/LDV), currently recommended for HCV
genotypes 1, 4, 5 and 6, and sofosbuvir/daclatasvir (SOF/DCV),
recommended for HCV genotypes 1, 3 and 4 [4]. However, since
their FDA approval, only 1.5 million HCV-infected patients were
treated with DAAs worldwide by the end of 2016 [1]. This low
treatment uptake can be attributed to a number of reasons,
including the high medication cost. The price for a 12-week course
of sofosbuvir in the US is currently US$84,000, despite calculations
that show a 12-week course can be profitably produced for just
US$86 (Figure 1) [5,6]. As part of the efforts to expand access,
voluntary licences have been issued in some lower-income
countries. These agreements explicitly prohibit supply to most
middle- and all high-income countries, where prices of DAAs
remain high [7].
As a result, patients all around the world are resorting to importing
generic versions of DAAs produced in India, China, Bangladesh
or Egypt for prices in the range of US$400–1300 per 12-week
treatment course [8]. Buyers’ clubs have been set up to act as a
third party and aid patients in accessing generic medication via
the internet. The import regulations vary by country; under UK
and Australian law it is legal for patients to import a 3-month
supply of medication for personal use [9,10]. In many other
countries it is legal for people to buy medications abroad, and
then to hand-carry these medications into their home country,
for their personal use.
The objective of this observational, retrospective study was to
assess the efficacy of generic DAAs imported by patients from
countries of manufacture via three internet buyers’ clubs.
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The relevance of this study is two-fold. Primarily, generic imports
for personal use would provide access to DAAs in the many
countries where treatment access remains limited. Secondly,
empirical assessment of treatment outcomes with imported
generics that are not licensed domestically, can provide an
important case study for the feasibility of using buyers’ clubs for
other diseases for which patented treatments are inaccessible due
to high prices.
Methods
To identify the buyers’ clubs in operation worldwide, we contacted
a number of community organisations who identified two
Australian buyers’ clubs (FixHepC and Hep C Treatment Without
Borders), the South-east Asian buyers’ clubs, and an Eastern
European buyers’ club. The results from FixHepC have been
reported elsewhere [11]. The three other buyers’ clubs asked
individuals who were using imported generic DAAs to fill out a
standardised data collection form along with a consent form. These
patients were typically treated with assistance from a clinician in
their country. In some cases, patients were advised on which
combination of DAAs to take from an online consultation with
the co-ordinators of their buyers’ club.
The information collected was:
• Patient demographics such as age, sex and country of residence;
• Baseline disease characteristics, such as HCV genotype, severity
of liver disease, treatments and doses;
• Planned dates of starting and stopping treatment;
• Manufacturer and marketer of each generic medication used;
and
• HCV RNA levels pre-treatment, during treatment (RVR), at the
end of treatment (EOT), and 4, 12 and 24 weeks after EOT
(SVR4, SVR12 and SVR24, respectively).
These surveys were conducted between March 2016 and March
2017. The methods used to assess the severity of liver disease
were not recorded in the questionnaire (i.e. Fibroscan versus liver
biopsy). We also did not record whether patients were co-infected
with hepatitis B or HIV.
The patient information was compiled into a single database. All
patients included in the analysis gave informed consent for their
treatment and response data to be shared. The questionnaires were
sent out, compiled and analysed as part of a research project
conducted at Imperial College London, UK.
The buyers’ clubs had different measures for ‘undetectable’ HCV
RNA. HCV RNA <25 IU/mL at 12 and 24 weeks post treatment
was taken as the definition of SVR12 and SVR24: a cure of HCV.
The data were summarised by type of treatment received:
sofosbuvir/ledipasvir (SOF/LDV) or sofosbuvir/daclatasvir (SOF/
DCV).
Participants were only included if they were taking generic versions
of both drugs in the combination regimen. Patients with HCV RNA
data available from their course of DAA treatment were included
in the analysis. In some cases, patients had to fund their HCV RNA
testing locally, and had very limited results available at follow-up.
Treatment efficacy was calculated by dividing the number of people
achieving SVR by the total number of people taking each
treatment regimen; 95% confidence intervals (CI) were calculated
using the Exact method.
Results
Overall, 616 patients were included in the final analysis; 199 from
the Australian buyers’ club, 205 from the South-east Asian buyers’
clubs and 212 from the Eastern Europe buyers’ club.
Baseline data are shown in Table 1. Patients were from 38 different
countries. Data were available on gender for 606 patients: 228/606
(38%) were female while 378/606 (62%) were male. No data were
available for 10 of the patients. The mean age was 44.3 years
(14–75 years) and the mean baseline plasma HCV RNA level was
6.9 log10 IU/mL; 52% had genotype 1; 5% genotype 2; 37%
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Figure 1. Lowest prices of sofosbuvir in selected countries
Table 1. Baseline characteristics
Characteristic Overall
n (%)
SOF/LDV
n (%)
SOF/DCV
n (%)
Number of participants* 616 276 (45) 340 (55)
Male 378 (61) 172 (62) 206 (61)
Female 228 (37) 97 (35) 131 (29)
Mean age (years) 44.3 — —
HCV genotype
Genotype 1 318 (52) 235 (85) 83 (24)
Genotype 2 31 (5) 1 (0) 30 (9)
Genotype 3 227 (37) 6 (2) 221 (65)
Genotype 4 11 (2) 8 (3) 3 (1)
Genotype 5 1 (0) 1 (0) 0 (0)
Genotype 6 28 (5) 25 (9) 3 (1)
Fibrosis (METAVIR score)
F0 114 (19) 49 (18) 65 (19)
F1 141 (23) 62 (22) 79 (23)
F2 206 (33) 91 (33) 115 (34)
F3 69 (11) 29 (11) 40 (12)
F4 (Cirrhosis) 68 (11) 30 (11) 38 (11)
Ribavirin
No RBV 520 (84) 241 (39) 279 (45)
RBV 96 (16) 35 (6) 61 (10)
Treatment duration
Median (weeks) 12.1 12.0 12.1
<12 179 (29) 88 (32) 91 (27)
12–23 (12–13) 378 (61) 165 (60) 213 (63)
≥24 59 (10) 23 (8) 36 (11)
HCV RNA at baseline
Mean (log10 IU/mL) 6.9
Mean (IU/mL) 7,898,550
* No data on gender were available for 10 patients
DCV: daclatasvir; HCV: hepatitis C virus; LDV: ledipasvir; SOF: sofosbuvir
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genotype 3; 2% genotype 4 and 5% genotype 6. METAVIR fibrosis
scores were 19% F0, 23% F1, 33% F2, 11% F3, and 11% F4. The
most common duration of treatment was 12 weeks.
Of the 616 patients treated, 276 (45%) received SOF/LDV (13%
with RBV), and 340 (55%) received SOF/DCV (61 with RBV). The
generic medication was marketed by 24 different companies and
organisations (Table 2). The majority (34%) were marketed by Cipla
Ltd, while 30% (173/572) of patients were taking DAAs sourced
from Hetero, 5.8% (33/572) from Natco and 4.2% (24/572) from
Mylan.
In terms of follow-up results, as of 17 June 2017, 375 (61%) had
data available for RVR; 237 (38%) for EOT; 303 (49%) for SVR4;
250 (41%) for SVR12 and 97 (16%) for SVR24.
An RVR was observed in 82% (146/177) of the patients treated
with SOF/LDV and 85% (168/198) of the patients treated with
SOF/DCV. The percentage of patients with HCV RNA <LLoQ was
99% (234/237) at end of treatment (EOT), 99% (299/303) SVR4
and 99% (247/250) at SVR12 (Table 3).
The SVR12 results by genotype are displayed in Figure 2. Of those
with genotype 1 HCV 98% (95% CI 95–100) had HCV RNA <25
IU/mL at SVR4 and 99% (95% CI 96–100) at SVR12. In genotype
3, the SVR4 rate was 99% (95% CI 95–100) and SVR12 was 98%
(95% CI 93–100). Sample sizes for all other genotypes were small,
but all patients exhibited SVR4 and SVR12 rates of >99%.
Discussion
This observational study demonstrates that internet-procured
generic DAAs have viral suppression rates in the same range as
originator drugs in Phase 3 trials [12]. Overall, 84% (314/375)
of patients had an RVR, 99% (234/237) reached undetectable
HCV RNA at EOT, 99% reached SVR4 (299/303) and 99%
(247/250) SVR12. In genotype 1 HCV patients the SVR12 rate
was 99% (138/139) and in genotype 3 SVR12 was 98% (95/97).
However, these were the results of on-treatment analyses. Only
21% of the patients had follow-up data available to evaluate SVR.
The survey did not include questions on discontinuing DAA
treatment, adverse events, or loss to follow-up.
These generic treatments could be purchased through buyers’ clubs
for a small percentage of the price for branded medications.
Patients paid US$ 500–1500 per treatment course, depending on
the type and duration of treatment required. These prices contrast
with retail prices of sofosbuvir of up to US$ 84,000 per 12-week
treatment course in the USA. However, it should be noted that
most providers of HCV treatment in the USA are offered significant
discounts from this $84,000 price – the size of these discounts
is normally kept confidential and so is hard to evaluate.
Our analysis is limited due to its observational nature, and by its
lack of a control group. As treatment and investigations were
guided by clinical intent only, pharmacokinetic measures, which
are commonly used to assess generic bio-equivalence, were not
obtained. Furthermore, safety data were not collected in this
analysis and the reasons as to the loss of follow-up were not
recorded. A more detailed analysis of the FixHepC buyers’ club,
presented in 2017 showed an overall SVR rate of 90%, with less
than 1% of patients lost to follow-up for HCV RNA at the SVR
time points [13].
The introduction of DAAs has been fairly recent and the function
of global buyers’ clubs is only beginning to emerge. This analysis
was limited by its small sample size and is, therefore,
unrepresentative of the less common HCV genotypes. Hence, this
study can be considered a pilot study for the efficacy of generics,
and will be updated as buyers’ clubs grow and more data are
available.
Table 2. Marketers of generic DAAs
Marketer Number of patients
SOF DCV LDV
Cipla 192 89 105
Hetero 182 103 70
Natco 45 17 16
Mylan 41 9 15
West Linfield Pharmacy (Compounded API) 12 3 11
Sun Pharma 18 9 8
Incepta 8 0 8
Mesochem 10 15 4
Other 3 9 4
Zydus 22 25 3
Pharmed Healthcare 3 0 3
UTH 3 0 3
Chinese API 3 31 1
Beacon 1 1 1
Dr. Reddy‘s 1 1 1
Marcyrl 6 5 0
Strides Arcolab 12 2 0
Emcure 5 0 0
Aark Pharmaceuticals 0 0 0
Augispov 1 0 0
Beximco 1 0 0
Pharco Corporation 1 0 0
No data available 46 21 23
DCV: daclatasvir; LDV: ledipasvir; SOF: sofosbuvir
Table 3. HCV RNA undetectable at follow-up by treatment regimen
Viral status Overall
n/total n (%)
SOF/LDV
n/total n (%)
SOF/DCV
n/total n (%)
RVR 314/375 (84) 146/177 (82) 168/198 (85)
EOT 234/237 (99) 108/110 (98) 126/127 (99)
SVR 4 299/303 (99) 131/134 (98) 168/169 (99)
SVR 12 247/250 (99) 104/104 (100) 143/146 (98)
SVR 24 96/97 (99) 30/30 (100) 66/67 (99)
DCV: daclatasvir; LDV: ledipasvir; SOF: sofosbuvir
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Figure 2. Percentage of patients with HCV RNA < LLoQ at SVR12
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The high efficacy of generic DAAs observed in this analysis was
not unexpected. Several companies currently manufacturing
generic sofosbuvir are licenced by Gilead, which provides them
with a full technology transfer of the manufacturing process [14].
Furthermore, the manufacturing processes of many of the
companies have been certified by national regulatory bodies. Such
companies include Mylan, Natco and also Cipla Ltd. Many
companies also provide Western markets with other medications
[14]. The Global Fund Expert Review Panel has listed four generic
versions of sofosbuvir to be used in its treatment programme, one
from Mylan and the other from Hetero Labs Ltd [15]. There are
concerns about the potential for counterfeit medications, however,
the results from these buyers’ clubs have shown no evidence that
this is true in the markets included. Furthermore, the risk of
counterfeit generic DAAs should not be any greater than that of
more expensive patented medications, which have a greater
financial incentive to counterfeit [7].
HCV drugs have now been included in the WHO prequalification
programme (WPP) [16,17]. The WPP results in the quick
procurement of cheaper quality-assured generic medications, which
optimises treatment outcomes and resource utilisation [18] to scale
up HCV treatment. The granting of the prequalification will aid
buyers’ clubs by assuring the integrity of the supply chain and
providing reassurance to HCV patients who source their treatment
from generic manufacturers.
While it is important to investigate the quality of imported generics,
questions remain as to how internet-procured medication can be
practically used within health systems. This includes regulating and
monitoring the online generic market while still respecting
intellectual property rights.
Part of the success of the Australian, eastern European and
South-east Asian buyers’ clubs is the result of the careful
monitoring of patients throughout treatment, in addition to the
available advice and the tailoring of treatment to each individual‘s
needs. The majority of online suppliers require a written doctor‘s
prescription for the purchase of DAA medications, although there
are some websites selling generic HCV DAAs for importation,
without the need for a prescription. However, in the UK, many
doctors are uncertain about the efficacy of generic antivirals and
are unwilling to prescribe and monitor patients using generic
medications, fearing they may lose their licences [19]. The authors
recommend that doctors should be better informed about the
legalities of recommendation, prescribing and monitoring of
patients on imported generic medication.
Patients are receiving conflicting advice regarding the safety of
medications procured online. The Australasian Society for HIV, Viral
Hepatitis and Sexual Health Medicine (ASHM) acknowledge
generic DAAs as a viable option for patients [20], whereas the
UK Medicines Healthcare and Regulatory Agency emphasise their
concerns over counterfeit medication [19]. The Swiss Experts in
Viral Hepatitis (SEVhep) have recognised that a large number of
patients have bought HCV medication online and have written
guidelines on how patients can safely access generic DAAs. In
addition to this, a Swiss health insurance company, Concordia,
included hepatitis C in its health insurance plan that reimburses
up to 75% of the cost of drugs imported from the FixHepC buyers’
club [21].
Furthermore, the legality of importing medication for personal use
differs internationally [22]. It is difficult for buyers’ clubs to police
these laws, and making them more explicit will enable internet
bought medication to be transparent in its services and
transactions.
In conclusion, treatment with legally imported generic DAAs,
purchased through online buyer‘s clubs, achieved high rates of
undetectable HCV RNA at the end of treatment, and SVR in 99%
patients evaluated to date. The efficacy observed is similar to Phase
3 trials of the branded medications. Mass treatment with the
current generic DAAs is a feasible and economical alternative for
accessing curative DAAs, while the high prices for branded DAAs
limit access to treatment. The results in this analysis of selected
buyers‘ clubs cannot be taken to prove that all medications for
hepatitis C procured online will be of a similar, high quality. Each
new supplier or buyers‘ club needs to be evaluated carefully to
ensure the quality of the medications procured.
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